Family history and women with ovarian cancer: Is it asked and does it matter? An observational study

International Journal of Gynecological Cancer

Volumn 22, Issue 2, 2012, Pages 254-259

  Lanceley, Anne ^a   Eagle, Zara ^b   Ogden, Gemma ^c   Gessler, Sue ^d   Razvi, Khalil ^c   Ledermann, Jonathan A ^e   Side, Lucy ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c BASILDON HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

BRCA1; BRCA2; Family history; Ovarian cancer

Indexed keywords

ADULT; ARTICLE; CANCER CENTER; CANCER THERAPY; CONSULTATION; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT REFERRAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMMUNICATION BARRIERS; ENGLAND; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDICAL HISTORY TAKING; MIDDLE AGED; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; YOUNG ADULT;

EID: 84858239325     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182392714     Document Type: Article

References (25)

1. Ford D, Easton DF, Stratton M, et al, and the Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676-679.
2. Evans G, Shenton A, Woodward E, et al. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer. 2008;8:155.
3. Schmeler KM, Lynch HT, Chen L, et al. Prophylactic surgery to reduce the risk of gynaecological cancers in the Lynch syndrome. N Engl J Med. 2006;354:261-269.
4. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009;3:138-150.
5. Cancer Research UK. Inherited genes and cancer risk. Cancer Research UK Web site. February 2, 2011. Available at: http://www.cancerhelp.org.uk/about- cancer/ causes-symptoms/genes-and-inherited-cancer-risk. Accessed May 5, 2011.
6. Goode EL, Chenevix-Trench G, Song H, et al. Ovarian Cancer Association Consortium. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010;42:874-879.
7. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376: 245-251.
8. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1.2011. 2011. Available at: http://www.nccn.org/professionals/physician-gls/ f-guidelines.asp. Accessed June 16, 2011.
9. National Institute of Clinical Excellence. CG41NICEguidance. NICE Web site. October 2006. Available at: http://www.nice.org.uk/nicemedia/pdf/ CG41NICEguidance. Accessed May 5, 2011.
10. Vasen HFA, Moslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007;44:353-362. (Pubitemid 46953715)
11. National Institute for Clinical Excellence. Ovarian cancer: the recognition and initial management of ovarian cancer. April 2011. Available at: http://www.nice.org.uk/guidance. Accessed April 30, 2011.
12. National Genetics Education and Development Centre. May 10, 2011. Available at: http://www.geneticseducation.nhs.uk/. Accessed May 23, 2011.
13. Wood ME, Stockdale A, Flynn BS. Interviews with primary care physicians regarding taking and interpreting the cancer family history. Fam Pract. 2008;25:334-340.
14. Wilson E, Clements A, Yudkin P, et al. Evaluation of the impact of two educational interventions on GP management of familial breast/ovarian cancer cases: a cluster randomised trial. Br J Gen Pract. 2001;51:817-821. (Pubitemid 32958618)
15. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. J Am Med Soc. 2010;292:1480-1489.
16. Lynch HT, Follett KL, Lynch PM, et al. Family history in an oncology clinic. Implications for cancer genetics. JAMA. 1979;242:1268-1272. (Pubitemid 10244424)
17. Department of Health. Our Inheritance, Our Future: Realising the Potential of Genetics in the NHS. London, UK: The Stationary Office; 2003.
18. Lacour RA, Daniels MS, Westin SN, et al. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol. 2008;111;132-136.
19. Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol. 2002;20:528-537. (Pubitemid 34072538)
20. Alberto VO, Harocopos CJ, Patel AA, et al. Family and personal history in colorectal cancer patients: what are we missing? Colorectal Dis. 2005;8:612-614.
21. Meyer LA, Anderson ME, Lacour RA, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynaecol. 2010;115:945-952.
22. Quillin JM, Bodurtha JN, Siminoff LA, et al. Exploring hereditary cancer among dying cancer patients-a cross-sectional study of hereditary risk and perceived awareness of DNA testing and banking. J Genet Couns. 2010;19:497-525.
23. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;1,121:353-357.
24. Soegaard M, Kjaer SK, Cox M, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 2008;14:3761-3767.
25. Daniels MS, Urbauer DL, Stanley JL, et al. Timing of BRCA1/ BRCA2 genetic testing in women with ovarian cancer. Genet Med. 2009;11:624-628.